These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 18363512)
21. The role of immune response in initiation and progression of chronic kidney disease. Shahbazi M; Smailnejad Ganji K; Mirzakhani M; Mohammadnia-Afrouzi M; Akbari R Iran J Kidney Dis; 2019 Sep; 13(5):283-299. PubMed ID: 31705744 [TBL] [Abstract][Full Text] [Related]
22. Arterial and Cellular Inflammation in Patients with CKD. Bernelot Moens SJ; Verweij SL; van der Valk FM; van Capelleveen JC; Kroon J; Versloot M; Verberne HJ; Marquering HA; Duivenvoorden R; Vogt L; Stroes ES J Am Soc Nephrol; 2017 Apr; 28(4):1278-1285. PubMed ID: 27799487 [TBL] [Abstract][Full Text] [Related]
23. Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. Kreiner FF; Kraaijenhof JM; von Herrath M; Hovingh GKK; von Scholten BJ Expert Rev Clin Immunol; 2022 Apr; 18(4):377-389. PubMed ID: 35212585 [TBL] [Abstract][Full Text] [Related]
28. Geriatric Nutritional Risk Index Is Associated with Unique Health Conditions and Clinical Outcomes in Chronic Kidney Disease Patients. Lin TY; Hung SC Nutrients; 2019 Nov; 11(11):. PubMed ID: 31739530 [TBL] [Abstract][Full Text] [Related]
29. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Chinnadurai R; Ritchie J; Green D; Kalra PA Nephrol Dial Transplant; 2019 Mar; 34(3):449-457. PubMed ID: 29390103 [TBL] [Abstract][Full Text] [Related]
30. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. Papademetriou V; Lovato L; Tsioufis C; Cushman W; Applegate WB; Mottle A; Punthakee Z; Nylen E; Doumas M; Am J Nephrol; 2017; 45(2):136-145. PubMed ID: 27992863 [TBL] [Abstract][Full Text] [Related]
31. Indoxyl sulfate: a candidate target for the prevention and treatment of cardiovascular disease in chronic kidney disease. Barisione C; Ghigliotti G; Canepa M; Balbi M; Brunelli C; Ameri P Curr Drug Targets; 2015; 16(4):366-72. PubMed ID: 25537654 [TBL] [Abstract][Full Text] [Related]
32. Design and optimization strategies for the development of new drugs that treat chronic kidney disease. Ramos AM; Fernández-Fernández B; Pérez-Gómez MV; Carriazo Julio SM; Sanchez-Niño MD; Sanz A; Ruiz-Ortega M; Ortiz A Expert Opin Drug Discov; 2020 Jan; 15(1):101-115. PubMed ID: 31736379 [No Abstract] [Full Text] [Related]
33. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification. Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993 [TBL] [Abstract][Full Text] [Related]
34. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Bertrand MJ; Tardif JC Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063 [TBL] [Abstract][Full Text] [Related]
35. Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes. Buyadaa O; Magliano DJ; Salim A; Koye DN; Shaw JE Diabetes Care; 2020 Jan; 43(1):122-129. PubMed ID: 31796570 [TBL] [Abstract][Full Text] [Related]
36. Is lipid management effective for all stages of CKD? Ku E; Campese V Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543 [TBL] [Abstract][Full Text] [Related]
37. Statin use in patients with diabetes and kidney disease: the Japanese experience. Koya D; Campese VM J Atheroscler Thromb; 2013; 20(5):407-24. PubMed ID: 23518468 [TBL] [Abstract][Full Text] [Related]
38. Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5. Marques GL; Hayashi S; Bjällmark A; Larsson M; Riella M; Olandoski M; Lindholm B; Nascimento MM Sci Rep; 2021 Jan; 11(1):2473. PubMed ID: 33510348 [TBL] [Abstract][Full Text] [Related]
39. Chronic Kidney Disease-Associated Inflammation Increases the Risks of Acute Kidney Injury and Mortality after Cardiac Surgery. Casas A; Mallén A; Blasco-Lucas A; Sbraga F; Guiteras J; Bolaños N; Castaño E; Torras J; Cruzado JM; Navarro E; Hueso M Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33353159 [TBL] [Abstract][Full Text] [Related]
40. Withaferin A protects against endoplasmic reticulum stress-associated apoptosis, inflammation, and fibrosis in the kidney of a mouse model of unilateral ureteral obstruction. Chen CM; Chung YP; Liu CH; Huang KT; Guan SS; Chiang CK; Wu CT; Liu SH Phytomedicine; 2020 Dec; 79():153352. PubMed ID: 33007732 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]